ArticleCancer science2026

Docetaxel-Induced Immune Activation Shows Antitumor Synergy With the Tumor-Targeted CD40 Agonist KK2269.

Yuta Tezuka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.